The synthesis of the tetratriacontapeptide amide corresponding to the revised structure of human big gastrin I is described. The fully protected peptide derivative was obtained by assembly in sequence order of the suitably protected fragments [1--9], [10--14] and [15--34] via the dicyclohexylcarbodiimide/N-hydroxysuccinimide and azide method, respectively. Upon removal of the protecting groups by exposure to trifluoroacetic acid and purification of the resulting crude product by chromatographic methods, human big gastrin I was obtained in satisfactory yields and at a high degree of purity. The identical immunological crossreactivities of natural and synthetic human big gastrin I using anti-porcine big gastrin I antiserum strongly supports the correctness of the newly proposed primary structure of this member of the gastrin family.

Download full-text PDF

Source

Publication Analysis

Top Keywords

big gastrin
20
human big
16
primary structure
8
gastrin
6
big
5
[total synthesis
4
human
4
synthesis human
4
gastrin revised
4
revised primary
4

Similar Publications

Association between post-operative hPG (circulating progastrin) detectable level and worse prognosis in glioblastoma.

ESMO Open

October 2023

Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.

Background: Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG, is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evaluated the prognostic value of plasma hPG in patients with isocitrate dehydrogenase-wild type glioblastoma after surgery.

View Article and Find Full Text PDF

Plasma hPG (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort.

BMC Cancer

April 2023

Cancer Epidemiology and Prevention Research, Alberta Health Services, 2210 - 2 Street SW, Calgary, AB, T2S 3C3, Canada.

Background: Recurrence and metastases are still frequent outcomes after initial tumour control in women diagnosed with breast cancer. Although therapies are selected based on tumour characteristics measured at baseline, prognostic biomarkers can identify those at risk of poor outcomes. Circulating progastrin or hPG was found to be associated with survival outcomes in renal and hepatocellular carcinomas and was a plausible prognostic biomarker for breast cancer.

View Article and Find Full Text PDF

Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report.

J Thorac Oncol

March 2023

Neuroendocrine Tumor Unit, ENETS Centre of Excellence, Endocrinology & Metabolism Department, Hadassah Medical Organization, Jerusalem, Israel; Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Introduction: The use of chromogranin A (CGA) as a circulating biomarker in lung carcinoids (LCs) is limited by low specificity and sensitivity. This study aimed to evaluate plasma progastrin-releasing peptide (ProGRPp) as an alternative to plasma CGA (CGAp), for the diagnosis and follow-up of LC.

Methods: ProGRPp and CGAp concentrations were measured in 107 patients with LC and 105 patients with benign lung disease (BLD).

View Article and Find Full Text PDF

Background: The neuroendocrine (NE) pathway cannot be ignored as a mechanism for castration-resistant prostate cancer (CRPC) progression. The neuromediator, gastrin-releasing peptide (GRP) may be involved in the aberrant activation of the normal androgen receptor (AR) and increased AR variants. This study focused on plasma levels of progastrin-releasing peptide (ProGRP) and examined the treatment outcomes with androgen receptor axis-targeted (ARAT) agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!